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ABSTRACT
Background: Most patients who use non steroid anti-in ammatory drug (NSAID) in long-term or high-dose 
will experience NSAID gastropathy that appears as dyspepsia complaints. The aim of this study is to assess 
the ef cacy of nabumeton and incidence of dyspepsia as side effect of treatment using nabumeton compared to 
meloxicam in patients with pain due to osteoarthritis.
Methods: Sixty patients with pain due to osteoarthritis at internal medicine clinic in Koja Hospital were 
included in this study and were given meloxicam or nabumeton within February 29th to March 25th 2013 period 
in double-blind manner. Primary disease pain degree and heartburn pain degree were evaluated three days 
after administration of the drug and a week was added if necessary. The statistical analysis used were student 
t-test to compare changes in pain scores between the 2 groups, and Chi-square test to assess differences in the 
number of dyspepsia in both groups.
Results: Pain scale reduction in meloxicam group was 0.57 ± 0.67 points, which is less than 1.27 ± 0.74 
points in nabumeton group. In addition, the average recurrence of heartburn in the meloxicam was 18 out of 30 
(60%) patients in total, while the average recurrence of heartburn in nabumeton was 2 out of 30 (60%) patients.
Conclusion: The use of nabumeton pain medication is better in terms of ef cacy and side effects of heartburn 
compared to meloxicam.
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ABSTRAK
Latar belakang: Sebagian besar pasien yang menggunakan obat anti in amasi non-steroid (OAINS) jangka 
panjang atau dosis tinggi akan mengalami gastropati OAINS yang muncul sebagai keluhan dispepsia. Tujuan 
penelitian ini adalah untuk menilai e kasi terapi nabumeton dan timbulnya efek samping dispepsia pada 
pemberian nabumeton dibandingkan dengan meloksikam pada pasien dengan nyeri akibat osteoartritis.
Metode: Enam puluh pasien dengan nyeri akibat osteoarthritis pada klinik penyakit dalam Rumah Sakit 
Koja didata dan masing–masing diberikan meloksikam atau nabumeton pada Febuari 2013 hingga Maret 2013 
secara acak, tersamar ganda. Skor nyeri sendi dan nyeri ulu hati dinilai pada hari ketiga dan kesepuluh. Analisa 
statistik yang digunakan ialah student t-test dan Chi-square test 
Hasil: Penurunan skala nyeri pada kelompok meloksikam sebesar 0.57 ± 0.67 yang lebih sedikit dibandingkan 
dengan kelompok nabumeton 1.27 ± 0.74. Selain itu, rata-rata timbulnya nyeri ulu hati pada kelompok meloksikam 
sebanyak 18 (60%) dari 20 pasien, sedangkan pada kelompok nabumeton hanya 2 (6%) dari 30 pasien.
Simpulan: Nabumeton lebih efektif menghilangkan nyeri dibandingkan meloksikam, dan efek samping nyeri 
ulu hati nabumeton lebih sedikit dibandingkan dengan meloksikam.
Kata kunci: osteoartritis, nyeri sendi, meloksikam, nabumeton
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INTRODUCTION
Non steroid anti-inflammatory drug (NSAID) 
is a commonly used clinical drug.1,2 Literature data 
indicate that as many as 85% of people aged over 
65 years showed osteoarthritis (OA) on radiological 
examination. Autopsy studies show almost every 
person over the age of 45 years showed signs of 
osteoarthritis in joints that bear the body weight 
function.3 Prevalence of radiological OA of the knee 
in Indonesia reached 15.5% in male and 12.7% 
in female. The main treatment of osteoarthritis is 
to provide anti-pain medication from  the class of 
NSAIDs. Most patients who use NSAIDs in long-term 
or high-dose will experience side effects of NSAID 
gastropathy which emerge as dyspepsia complaints. 
Although osteoarthritis is not a fatal disease, but the 
side effects of NSAIDs can cause gastrointestinal 
bleeding resulting fatal conditions.4,5 NSAIDs cause 
gastropathy through 2 ways: topically and systemically. 
Prostaglandin (PG) produced by COX-2 pathways 
causes in ammation, pain and fever, so it is expected 
that selectively COX-2 inhibitor NSAID is relatively 
safer than conventional NSAIDs.6
In addition to the use of NSAIDs that selectively 
inhibit COX-2, there was another attempt to avoid NSAID 
gastropathy, which is by using a non-acid NSAIDS 
like nabumeton.7,8 Both of these drugs, nabumeton and 
meloxicam are widely used to overcome joint pain, as 
well as in Internal Medicine Department, Koja Hospital. 
However, the study to assess the ef cacy of both in 
dealing with pain has not been done, and dyspepsia 
adverse effects arising from the use of nabumeton or 
meloxicam. Therefore, this research aims to compare 
the clinical ef cacy and side effects of nabumeton and 
meloxicam in management of pain in osteoarthritis patient 
population, both in outpatients and hospitalization setting 
in Internal Medicine Department, Koja Hospital.
METHOD
This study used double-blind design, with study 
population of all patients with osteoarthritis or joint 
disorders at Internal Medicine Clinic in Koja Hospital. 
Samples were taken using a consecutive sampling 
method. Inclusion criteria were patients with symptoms 
of OA and joint pain. Exclusion criteria were other 
diseases presented with pain, not due to OA or have 
no complaints of stomach pain before. Patients who 
do not comply or are taking other drugs than those 
prescribed or not taking medications as suggested will 
be dropped out.
Figure 1. Work ow study describing patients treatment
Randomly 30 patients will be clustered in group A, 
while 30 other patients will be grouped in group B. One 
group was given meloxicam 15 mg once daily for 3 days 
and the other group was given nabumeton 500 mg twice 
daily for 3 days. Both meloxicam and nabumeton were 
given in their original factory preparation. Subjects and 
investigators were masked to medication received from 
each group; drugs code were revealed at the end of the 
study. Both groups would be assessed (post-test) on day 
3. If pain was not reduced, then second post-test on day 
10 was performed. Quality of the joint pain presence and 
dyspepsia complaints were assessed. If there were no 
more complaints of dyspepsia and joint pain, therapy 
was stopped. When complaint of joint pain was reduced 
and no complaint  of heartburn was present, therapy 
was continued and data collecting (post-test) was 
performed at day 10. If joint pain was reduced and no 
dyspeptic complaints was present, therapy was followed 
by administration of additional sucralfate 15 cc thrice 
times, and data collection (post-test) was performed at 
day 10. If there were no pain changes and no heartburn 
was present, therapy was continued. If there was no 
change in pain, but gastric pain was present, drugs were 
replaced by other drug from other groups. If the pain 
worsened or persisted after the drug was prolonged and 
no gastric pain was present, tramadol was given with 
1 tablet thrice a day. When therapy was extended for 
a week, the pain scale was reviewed in the next week. 
The work ow can be seen in Figure 1.
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Pain assessment was performed by the subjects, by 
answering questions given about the pain scale. Pain 
scale assesment used  ve-point verbal rating scale 
(VRS) as described in Table 1.9
Table 1. Pain assessment score
Pain Scale Score
No pain 1
Mild pain 2
Moderate pain 3
Severe pain 4
Worst possible pain 5
Tab le 2. Subject characteristic
Variable
Total Group
Subject (% or SD) A (% or SD) B (% or SD)
Subject (n) 60 (100%) 30 (50%) 30 (50%)
Sex
 Male 9 (15%) 5 (16%) 4 (13%)
 Female 51 (85%) 25 (83.3%) 26 (86%)
Mean of age 55 ± 11.62 55.5 ± 10.95 55.2 ± 12.43
Age group (years old)
 < 40 5 (8.3%) 1(3.3%) 3 (10%)
 40-60 36 (60%) 19 (63.3%) 18 (60%)
 > 60 19 (31%) 10 (33.3%) 9 (30%)
BMI (kg/m2)
 Underweight (<18.5) 3 (5%) 2 (6%) 1 (3)
 Normal (18.5-24.9) 24 (40%) 13 (43) 11 (36.7)
 Overweight (25-29.9) 24 (40%) 13 (43) 11 (36.7)
 Obese (>30) 9 (15%) 2 (6) 7 (23.3)
Pain scale mean 
 Pre-test 3.28 ± 0.82 3.23 ± 0.82 3.33 ± 0.84
 Post-test 2.36 ± 1.07 1.96 ± 1.03 2.76 ± 0.97
 Reduction 0.92 ± 0.79 1.27 ± 0.74 0.57 ± 0.67
Gastric pain incident rate 20 (33.3%) 2 (6.7%) 18 (60%)
BMI: body mass index
average scale pain obtained in meloxicam group was 
2.76 (SD = 0.97) and in group nabumeton was 1.96 
(SD = 1.03). Thus a decrease in the pain scale 
meloxicam group was 0.57 (SD = 0.69), which were 
less than the nabumeton 1.27 (SD = 0.69). Heartburn 
side effects in meloxicam group were present in 18 
out of 30 (60%) patients. Gastric pain side effects 
on nabumeton group were amounted in 2 out of 30 
(6.67%) patients. The data of subject characteristics 
is presented in Table 2.
A total of 16 (26.6%) subjects stated that joint pain 
disappeared as observation was completed. Twenty 
three (38.3%) subjects stated joint pain was reduced on 
day 3. While the remaining 21 (35%) subjects stated 
constant or increased joint pain; thus, therapy was 
continued and was observed in the second post-test. 
In the second post test, it was stated that two subjects 
experiened disappeared joint pain and 19 of them 
improved. Monitoring results of pain relief and side 
effects dyspepsia appearance shown in Figure 2.
On day 3 monitoring, from 60 subjects studied, 
66.7% had no dyspeptic complaints. The remaining 
33.3% complained of heartburn, 2 subjects (3.3% of 
the sample population) belong to nabumeton group and 
18 subjects (30% of the sample population) belong to 
meloxicam group.
In the  rst phase of post test decrease pain scores 
was obtained from both groups. In group A pain 
RESULT
Research has been conducted to 60 patients with 
joint pain caused by osteoarthritis, in the period of 
February 2013 to March 2013. Of 9 (15%) subject 
were female. After a block randomization, 30 subjects 
were assigned to group A (nabumeton) and the other 
30 subjects to group B (meloxicam). Mean age of 
these subjects was 55 years, with 5 (8.3%) subjects 
aged less than 40 years, 36 (60%) subjects aged 
between 40-60 years and 19 (31%) subjects aged 
over 60 years. A total of 24 (40%) subjects had a body 
mass index (BMI) classi ed as normal, 24 (40%) 
subjects overweight (25-30 kg/m2), 3 ( 5%) subjects 
underweight (< 18.5 kg/m2), and 9 (15%) subjects 
obese (> 30 kg/m2). Average pain scale pre-test group 
meloxicam 3.33 (SD = 0.84) and in group nabumeton 
3.23 (SD = 0.82), while from the  rst post-test (day 3) 
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Figure 2. Monitoring results of pain relief and the emergence of dyspepsia side effects
Figure 3. The average pain score reduction was greater in group 
A compared to group B, with p < 0.00
score decreased from 3.23 ± 0.82 to 1.96 ± 1.03, with 
difference of 1.27 ± 0.74, whereas in group B pain 
score decreased from 3.33 ± 0.84 to 2.76 ± 0.97, with 
difference of 0.67 ± 0.57. Decrease in pain score was 
greater than meloxicam group. Student t-test con rmed 
that the pain score reduction was signi cantly different, 
with p < 0.000 (Figure 3).
DISCUSSION
 Although the literature stated that the prevalence 
of radiological knee OA in Indonesia reached 15.5% 
in male and 12.7% in female,2 our study showed more 
female patients came for treatment with symptoms of 
OA and joint disorders. This might be caused by the 
fact that female have the time to come to the Internal 
Medicine Clinic in Koja Hospital which operates at work 
hour, while the male still have to work on work hour.
Dominant age group was between 40 - 60 years 
by 36 (60%) subjects, followed by the age group > 60 
years by 19 (31%) subjects, and age groups < 40 years 
by 5 (8.3%) subjects. This shows that the incidence 
Figure 4. Average dyspepsia emergence rate in group A than 
in group B, with p < 0.00
Dyspepsia occurred in both groups, with a 
number of different events. At nabumeton group, 
it was obtained that 2 (6.7%) subjects complained 
of dyspepsia, while on meloxicam group 18 (60%) 
subjects had the same complaint. By using the Chi-
square test, statistically signi cant differences was 
found, with p < 0.000 (Figure 4).
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of OA and other joint disorders is more in old age 
(> 40 years) than in younger age (< 40 years). As stated 
by Loeser, age is a major risk factor of OA, possibly 
due to aging in cells and tissues that make the joints 
more susceptible to damage and less able to sustain 
homeostasis.9
Subjects with a BMI of overweight and obese have 
a large portion of our total subjects. This pointed that 
excess of weight has greater tendency to experience 
joint disorders. These  ndings af rm Tukker et al 
report, that overweight is associated with osteoarthritis, 
especially in the hip and knee.10
Average pain score reduction was more superior 
in nabumeton group, with the score of 1.27 compared 
with 0.57 in meloxicam group. Meloxicam result on 
statistical tests for group differences in pain scores 
reduction 1.27 ± 0.74 in nabumeton group and 0.57 ± 
0.9 in meloxicam group with p less than 0.000. This 
difference was statistically signi cant.
Waranugraha et al reported that types of NSAIDs 
do not provide the gastropathy differences in clinical 
symptoms, as well as the usage manner, either periodic 
or continous.11
However, from the results of our study on the 
prevalence of heartburn nabumeton by 2 subjects, 
i.e. 6.67% in the whole group nabumeton and 
3.3% compared to the entire population, while the 
meloxicam total of 18 subjects, i.e. 60% in the whole 
group or 30% of all population. Statistical test result 
for differences in incidence rates of dyspepsia: 
nabumeton group 2 subjects, meloxicam groups 18 
subjects, with p less than 0.000. This difference was 
statistically signi cant.
CONCLUSION
The use of Nabumeton is more advisable than the 
use of conventional NSAIDs meloxicam in terms of 
ef cacy and prevention of side effects such as gastric 
pain. Further study is required to assess the ef cacy 
and side effects of this drug with a better study design, 
larger sample size, and longer treatment duration. 
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